(2S)-2-[[(3S,8S)-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-7-(3-phenylpropyl)-3,6,8,9-tetrahydro-2H-[1,4]dioxino[2,3-g]isoquinoline-8-carbonyl]amino]-3-[4-(2,3-dimethylpyridin-4-yl)phenyl]propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[(3S,8S)-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-7-(3-phenylpropyl)-3,6,8,9-tetrahydro-2H-[1,4]dioxino[2,3-g]isoquinoline-8-carbonyl]amino]-3-[4-(2,3-dimethylpyridin-4-yl)phenyl]propanoic acid
• 化学式: C₅₀H₄₇Cl₂N₃O₆
• 分子量: 856.8
• InChiKey: YGFAFIIGGHLYDM-GAYZTXEMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  61
• 可旋转键数：
  14
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• COMBINATIONS OF A GLP1R AGONIST AND METFORMIN AND USE THEREOF FOR THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS
  申请人：vTv Therapeutics LLC

  公开号：EP2945618A1

  公开（公告）日：2015-11-25
• THERAPEUTIC USES OF GLP1R AGONISTS
  申请人：vTv Therapeutics LLC

  公开号：EP3790549A1

  公开（公告）日：2021-03-17
• [EN] COMBINATIONS OF A GLP1R AGONIST AND METFORMIN AND USE THEREOF FOR THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS<br/>[FR] COMBINAISONS D'UN AGONISTE DU GLP1R ET DE METFORMINE, ET LEUR UTILISATION POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2 ET D'AUTRES TROUBLES
  申请人：TRANSTECH PHARMA LLC

  公开号：WO2014113357A1

  公开（公告）日：2014-07-24

  The present invention provides uses of a glucagon-like peptide 1 receptor agonist in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GLP1R agonist and metformin.
• [EN] THERAPEUTIC USES OF GLP1R AGONISTS<br/>[FR] UTILISATIONS THÉRAPEUTIQUES D'AGONISTES DE GLP1R
  申请人：VTV THERAPEUTICS LLC

  公开号：WO2019217165A1

  公开（公告）日：2019-11-14

  Methods of using glucagon-like peptide 1 receptor (GLP1R) agonists are generally disclosed herein. In certain aspects, the disclosure provides methods of treating type 2 diabetes that include administering a GLP1R agonist according to certain dosage regimens. In certain other aspects, the disclosure provides methods of treating obesity that include administering a GLP1R agonist according to certain dosage regimens. In certain other aspects, the disclosure provides methods of lowering glycated hemoglobin (for example, lowering HbA1c) that include administering a GLP1R agonist according to certain dosage regimens. Compositions containing GLP1R agonists and their manufacture, for example, for use as a medicament are also disclosed herein.